General News

International Clinical Trials Day 2018

Posted in General News Published by Bethan Warman 21 May 2018

International Clinical Trials Day 2018

International Clinical Trials Day is celebrated on 20th May each year in recognition of the clinical trials conducted around the world, which ensure that research from the laboratory can be translated into patient benefit. The progress that is continuing to be made in cancer research, resulting in cancer survival rates doubling in the last 40 years, would not be possible without the researchers, clinicians, nurses and, of course, patients that are involved in clinical trials each year.

Fellows inaugurated at new Rutherford Academy of Population Genomics and Health Data Science

Posted in General News, Grants & Awards Published by Bethan Warman 16 May 2018

Fellows inaugurated at new Rutherford Academy of Population Genomics and Health Data Science

Queen Mary University of London has appointed four research fellows to its new Rutherford Academy of Population Genomics and Health Data Science, funded by the Medical Research Council and UK Research and Innovation’s Rutherford Fund. Two of the fellows include BCI’s Dr Kit Curtius and Dr Dayem Ullah.

Queen Mary’s new Rutherford Academy will be aligned to its research as a partner of the London substantive site of Health Data Research UK - a major new initiative to transform health through data science. Forty two of these prestigious fellowships were awarded following a rigorous national competition, resulting in four fellowships at Queen Mary out of a total of fourteen awarded to London universities.

London Pancreas Workshop 2018

Posted in General News, BCI Spotlight Articles, Events Published by Bethan Warman 11 May 2018

A forum for state-of-the-art clinical and basic research in pancreatic cancer

London Pancreas Workshop 2018

On Friday 4th May, BCI hosted the seventh London Pancreas Workshop, co-organised by Prof Hemant Kocher and our Director Prof Nick Lemoine, which attracted delegates from across Europe and America, with over 140 attendees in total. The biennial event is recognised as a forum for state-of-the-art clinical and basic research in pancreatic cancer.

The areas of focus for this year’s workshop were diagnostics, clinical trials and preclinical work for targeting pancreatic cancer. We heard a variety of interesting talks in these areas, delivered by researchers renowned in their fields.

Research reveals how breast cancer drug can accelerate cancer cell growth

Posted in General News, Publications Published by Bethan Warman 01 May 2018

Research reveals how breast cancer drug can accelerate cancer cell growth

The breast cancer drug lapatinib which is designed to shrink tumours can sometimes cause them to grow in the lab, according to a new study published in eLife. By understanding the molecular basis of this phenomenon, scientists hope that their findings will lead to safer treatment options and drug design in the future.

Lapatinib is used in combination with other cancer drugs and chemotherapy to treat patients with a particular type of advanced breast cancer, but failed clinical trials as a stand-alone treatment.

Using a modified adenovirus to overcome treatment resistance in prostate cancer

Posted in General News, Publications Published by Bethan Warman 27 April 2018

Using a modified adenovirus to overcome treatment resistance in prostate cancer

Researchers from BCI’s Centre for Molecular Oncology, led by Dr Gunnel Halldén, have identified a mechanism by which a modified flu-like virus, called AdDD, is able to negate resistance to a drug called mitoxantrone and increase tumour cell killing in prostate cancer models. This mechanism is dependent on B-cell lymphoma 2 (Bcl-2)- a protein involved in the regulation of cell death (apoptosis).

Recent statistics have shown that prostate cancer is now the third biggest cancer killer in the UK, claiming the life of one man every 45 minutes. Here at the BCI, prostate cancer is a key focus of research and our researchers endeavour to identify factors that influence prostate cancer progression and therapeutic response.

BCI and KCL collaboration develops a clinically-relevant CAR T cell imaging system

Posted in General News, Publications Published by Bethan Warman 19 April 2018

BCI and KCL collaboration develops a clinically-relevant CAR T cell imaging system

A collaboration involving researchers from BCI’s Centre for Molecular Oncology, led by Dr Jane Sosabowski, and the ImmunoEngineering Group of King’s College London (KCL), led by Dr Sophie Papa, has developed an effective and clinically-relevant imaging system to monitor chimeric antigen receptor (CAR) T cells within the body. This system reduced the tumour burden in a pre-clinical model of prostate cancer and allowed for repeated and non-invasive assessment of CAR T cell localisation.

UK charities join forces to fund the work of Dr Angus Cameron

Posted in General News, Grants & Awards Published by Bethan Warman 05 April 2018

Supporting vital research on pancreatic cancer

UK charities join forces to fund the work of Dr Angus Cameron

BCI’s Dr Angus Cameron, Centre for Tumour Biology, is to receive joint funding from Worldwide Cancer Research and Pancreatic Cancer Research Fund (PCRF) to support vital research on pancreatic cancer. The charities have awarded equal sums totalling £235,000 to support the work of Dr Cameron and his laboratory group.

Pancreatic cancer is diagnosed in approximately 9,900 individuals annually in the UK and, although this disease accounts for only 3% of the total cancer cases diagnosed each year in the UK, the prognosis is dismal- with less than 1% of patients surviving for 10 years or more.

Determining the mechanisms of response and resistance to treatment in bladder cancer

Posted in General News, Publications Published by Bethan Warman 29 March 2018

Improving the efficacy of immune checkpoint inhibitors

Determining the mechanisms of response and resistance to treatment in bladder cancer

A worldwide collaboration involving BCI’s Prof Thomas Powles, Centre for Experimental Cancer Medicine, has revealed mechanisms involved in the development of response and resistance to an immune checkpoint inhibitor in metastatic urothelial cancer. The findings may highlight ways to improve the efficacy of this treatment in the hope of achieving long-term remission for patients.

Immune checkpoint inhibitors, a class of immunotherapeutic drug, have been shown to induce robust responses in patients with a variety of cancer types. These drugs block proteins that prevent the immune system from destroying cancer cells.

Follicular lymphoma marked by spatial tumour heterogeneity

Posted in General News, Publications Published by Bethan Warman 23 March 2018

A challenge for targeted therapy

Follicular lymphoma marked by spatial tumour heterogeneity

A research team at the BCI, Queen Mary University of London, led by Dr Jessica Okosun, Centre for Haemato-Oncology, has found that tumours at different sites within the same patient with follicular lymphoma can be genetically diverse. This suggests that a sole biopsy is incapable of capturing all the genetic events in any given individual and presents a significant challenge when providing targeted therapies to treat this disease.

Follicular lymphoma is an incurable blood cancer that is characterised by the production of abnormal B lymphocytes (a type of white blood cell involved in fighting infection) that accumulate primarily in the lymph nodes and bone marrow. Approximately 2,300 cases of follicular lymphoma are diagnosed in the UK each year.

Seema Jaswal visits the BCI

Posted in General News, Engagement Published by Bethan Warman 15 March 2018

Celebrating International Women's Day

Seema Jaswal visits the BCI

Last Thursday was International Women’s Day- a day that celebrates the social, political, cultural and economic achievements of women from all over the world. Recently, an inspirational woman, Seema Jaswal- a television and radio presenter- visited us here at the Barts Cancer Institute (BCI) to meet some of our researchers and find out more about the cutting edge research that goes on here.

Seema’s TV career began at Sky Sports where she worked as a Runner before receiving her first presenting job on CBBC Sports Round. Seema’s successful career has since seen her host a variety of events, including the Indian Super League, India’s FIFA U17 World Cup and the Premier League. Last year, Seema was named as one of We Are The City’s Inspirational Women.

[12 3 4  >>  
This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.